Pfizer considering cost cuts as Americans yawn at future COVID shots
Vials of the Pfizer-BioNTech COVID-19 vaccine are at Walter Reed National Military Medical Center in Bethesda, Maryland, Dec. 14, 2020, following the vaccine's emergency use authorization by the Food and Drug Administration. (DoD photo by Lisa Ferdinando)
(JUST THE NEWS) – Pfizer says it is considering cutting costs in response to potential losses as fewer Americans take the pharmaceutical manufacturer's COVID-19 vaccine and antibody treatment.
Pfizer made the announcement on a quarterly earnings call Tuesday, reflecting the public's apathy towards the virus and the declining government support for COVID products, according to Axios.
The company estimated in January that 100 million COVID vaccines would be administered throughout the United States in 2023, with Pfizer accounting for 60% of the vaccines.
The post Pfizer considering cost cuts as Americans yawn at future COVID shots appeared first on WND.